Ermium Therapeutics achieves breakthrough R&D progress with its proprietary CXCR4-targeted functionally selective immunomodulator

Besides the already published in vitro and vivo proof of concept data, Ermium established, with a proprietary CXCR4-targeted non antagonist immunomodulator, proof of concept in three in vivo models, including in a well-known murine disease model of systemic lupus erythematosus.